ðɪ ɪfˈɛkt ʌv tˌiːˌɑːɹkˈeɪ bˈiː slˈæʃ bˌiːdˌiːˌɛnˈɛf sˈɪɡnəlɪŋ ˌɔn ˌeɪdˈiː pæθˈɑːlədʒi hˈæzbiːn ʃˈoʊn təbi ɪn pˈɑːɹt mˈiːdɪˌeɪɾᵻd baɪ ɐn ˈɪŋkɹiːs ɪn dˈɛltəsˈɛkɹɪtˌeɪs lˈɛvəlz, vˈaɪəɹ ɐn ˌʌpɹɪɡjʊlˈeɪʃən ʌvðə dʒˌeɪˌeɪkˈeɪ tˈuː slˈæʃ stˈæt θɹˈiː pˈæθweɪ ænd sˈiː slˈæʃ ɛbpbˈeɪɾə dˈaʊnstɹiːm ʌv tˌiːˌɑːɹkˈeɪ bˈiː.
The effect of TrkB/BDNF signalling on AD pathology has been shown to be in part mediated by an increase in δ-secretase levels, via an upregulation of the JAK2/STAT3 pathway and C/EBPβ downstream of TrkB.